Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 58.17

+3.9%

Dec 4 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Arthur Radley	5/22/2007 12:08:30 PM
	Read Replies (1) of 52153

GSK yesterday and Novartis today... WASHINGTON, May 22 (Reuters) - Severe kidney failure and in some cases death have been reported in patients using Novartis AG's (NOVN.VX: Quote, Profile , Research) (NVS.N: Quote, Profile , Research) iron overload drug Exjade, the U.S. Food and Drug Administration said on Tuesday. Patients using the drug, which removes excess iron from certain organs in patients receiving blood transfusions, also reported various blood deficiencies known as cytopenias that in some cases also led to death, the FDA said. The agency added that Novartis has already included the new concerns on the drug's label. The company has also notified doctors, who the FDA said should take steps to monitor at-risk patients.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next